ArticleFrontiers in oncology2025
Graph-based analysis of histopathological images for lung cancer classification using GLCM features and enhanced graph.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An Intelligence-Based Hybrid CNN-GAT Framework Optimized by the Whale Optimization Algorithm for Clinical Lung Cancer Classification from Chest CT Images.Journal of imaging informatics in medicine · 2026Article
- HiGATE: hierarchical graph attention for multi-scale tissue encoder in computational pathology.Frontiers in oncology · 2026Article
- AI driven network pharmacology: Multi-scale mechanisms of traditional Chinese medicine from molecular to patient analysis.Computational and structural biotechnology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains a leading cause of global cancer mortality, demanding precise diagnostic tools for accurate subtype classification. This paper introduces a novel Enhanced GraphSAGE (E-GraphSAGE) framework that integrates graph-based deep learning (GBDL) with traditional image processing to classify lung cancer subtypes-Adenocarcinoma (ACA), Squamous Cell Carcinoma (SCC), and Benign Tissue (BNT)-from H&E-stained Whole-Slide Images (WSIs). Our methodology leverages Gray-Level Co-occurrence Matrix (GLCM) features to quantify tissue texture, constructs a Sparse Cosine Similarity Matrix (SCSM) to model spatial relationships, and employs DeepWalk embeddings to capture topological patterns. The E-GraphSAGE architecture optimizes neighborhood aggregation, incorporates dropout regularization to mitigate overfitting, and utilizes Principal Component Analysis (PCA) for dimensionality reduction, ensuring computational efficiency without sacrificing diagnostic fidelity. The model is validated on multicell Lymphocytic cancer classification of Diffuse Large B-cell lymphoma (DLBCL), Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL), experimental results demonstrate superior performance, achieving 96% training accuracy and 90% validation accuracy, with an F1-score of 0.91 and AUC-ROC of 0.95 (DLBCL), 0.92 (FL), and 0.89 (SLL). Comparative analysis against state-of-the-art models (GAT, GCN, ResNet-50, ViT) reveals our framework's dominance, attaining an overall accuracy of 0.90, F1-score of 0.905, and macro-average AUC-ROC of 0.93. While maintaining 25.7 sec/slide inference speed-significantly faster than competing methods. This study advances computational pathology by unifying Graph Neural Networks (GNN) with interpretable feature engineering, offering a scalable, efficient solution for cancer subtype classification. The framework's ability to model multi-scale histopathological patterns-from cellular interactions to tissue architecture-positions it as a promising tool for clinical decision support, enhancing diagnostic precision and patient outcomes in hemato-pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.